Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sisunatovir (RV521) in Infants with RSV LRTI
NCT04225897Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of sisunatovir in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Nov 2019; status: terminated.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04225897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225897.